Wet Macular Degeneration Market Report and Forecast 2025-2034
Description
The wet macular degeneration market attained a value of USD 9.53 Billion in 2024, driven by the rising aging population and advancements in treatment options across the 8 major markets. It is expected to grow at a CAGR of 5.90% in the forecast period of 2025-2034, and attain a value of USD 16.91 Billion by 2034.
Wet Macular Degeneration Market Overview
Wet macular degeneration (or neovascular AMD) is a long-term disease that affects central vision in senior citizens. Wet macular degeneration is a more serious condition and is a type of AMD marked by a severe, rapid loss of central vision in the retina where macular degeneration has occurred. This condition develops when the small blood vessels beneath the macula of the retina swarm and ooze out fluids like blood. While the rest of the retina is involved in the peripheral vision, the macula is responsible for the central vision, necessary for reading or identifying faces. Symptoms are effectively controlled by early intervention, and medications like anti-VEGF injections can delay the progression of the condition.
Wet Macular Degeneration Market Growth Drivers
Increasing Aging Population to Boost the Market Growth
In a report, the World Health Organization (WHO) highlighted that with increasing life expectancy, a large number of individuals will reach 60 or older by 2050. Wet macular degeneration cases are bound to surge with the increasing incidence of the geriatric population base, leading to increased demand for treatment among the elderly with vision-related diseases.
FDA Approval Boosts the Market Growth
In September 2024, Pavblu, the fifth biosimilar referencing Eylea (aflibercept), was approved by the FDA for the treatment of retinal conditions such as wet age-related macular degeneration. Pavblu, developed by Amgen, was approved after a phase 3 study with 576 patients from various countries. It is one of several biosimilars that got approval in 2024, along with Yesafili, Opuviz, Ahzantive, and Enzeevu. There is a growing emphasis on early detection and preventive healthcare. Increasing approvals from essential regulatory authorities is expected to boost the market value in the forecast period.
Wet Macular Degeneration Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Development of Long-Acting Treatments
Companies are investigating extended-duration therapies for wet AMD to decrease the need for invasive surgeries and enhance patient adherence. Innovations such as port delivery systems and sustained-release formulations are designed to prolong injection intervals, possibly decreasing treatment demands and improving patient quality of life.
Emergence of Gene and Stem Cell Therapy to Boost Wet Macular Degeneration Market Demand
Gene and stem cell therapies demonstrate promise in targeting AMD. Researchers are striving to repair genetic mutations linked to wet macular degeneration and restore damaged retinal cells. Research studies show that there is a possibility of restoring vision and preventing disease progression in wet macular degeneration, indicating that these treatments may have a significant effect on the market for this condition.
Adoption of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnosis
Artificial Intelligence and machine learning are changing the landscape of retinal disease diagnosis by facilitating early detection and monitoring of macular degeneration, thus enhancing patient outcomes with prompt intervention. AI-driven diagnostic technology examines OCT images, recognizing levels of illness and tailoring treatment strategies.
Advancements in Treatment Options Drive Market Growth
New developments in the field of ophthalmology and biotechnology have made it possible to develop ways of treating wet macular degeneration. Novel technologies such as gene therapies and new ways of drug delivery as well as heightened interest in patient-specific approaches are stimulating the development of the market.
Wet Macular Degeneration Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Stage:
Market Segmentation Based on the Route of Administration Set to Witness Substantial Growth
The market is segmented into intravenous route and intravitreal route based on the route of administration. Among these, the intravitreal method is expected to dominate the market because it directly administers drugs into the eye, resulting in improved treatment results and fewer overall side effects. Medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea) are often given through injections directly into the eye. This technique enables focused treatment of the retina, effectively preventing the growth of abnormal blood vessels. Due to its established efficacy and lower risks when compared to systemic delivery, intravitreal therapy continues to be considered the preferred treatment method for wet AMD.
Segmentation Based on End User Holds a Significant Market Share
The market is divided intohospitals, clinics, ambulatory surgical centers, homecare settings, and others. Among these, hospitals and clinics are expected to dominate the market because of their specialized ophthalmologists and advanced diagnostic equipment. They provide thorough treatment, which includes giving anti-VEGF medications such as Lucentis and Eylea via injections into the eye. Ambulatory surgical centers also hold a substantial share due to their affordability, while homecare settings are utilized for remote monitoring and occasional medical care.
Wet Macular Degeneration Market Analysis by Region
Based on region, the market report covers the United States, EU-4, and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. Due to advanced healthcare systems and substantial investment in research, the United States is expected to dominate the market. Factors like increasing elderly populations and lifestyle-related risks impact the market in this area. The government's backing promotes market expansion through leadership in clinical trials and innovative treatments such as targeted therapies and immunotherapies. The market is growing due to greater emphasis on early detection and personalized treatment choices.
Leading Players in the Wet Macular Degeneration Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG
Bayer AG, headquartered in Leverkusen, Germany, is a leading pharmaceutical company in the age-related wet macular degeneration (AMD) market. Their primary product, Eylea (aflibercept), is a very effective treatment for wet AMD that can preserve and even improve vision. Bayer remains committed to investing in the research and development of new AMD therapies.
F-Hoffmann La Roche Ltd.
Established in 1896 and headquartered in Basel, Switzerland. Roche specializes in ophthalmic disorder drugs. They developed Lucentis, a popular anti-VEGF therapy drug for wet AMD, through Genentech. They are working on new delivery methods and long-acting formulations to reduce reliance on frequent injections in AMD treatment, leveraging their biopharmaceutical expertise.
Pfizer Inc.
Pfizer Inc. is a significant player in the wet age-related macular degeneration (AMD) market, which is highly competitive and poised for growth due to the aging global population and the rising prevalence of eye disorders.
Novartis AG
Novartis AG is a leading player in the market, primarily through its flagship drug, Lucentis (ranibizumab), a pioneering anti-VEGF therapy developed in partnership with Genentech.
Other companies include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV, among others.
Key Questions Answered in the Wet Macular Degeneration Market
Wet Macular Degeneration Market Overview
Wet macular degeneration (or neovascular AMD) is a long-term disease that affects central vision in senior citizens. Wet macular degeneration is a more serious condition and is a type of AMD marked by a severe, rapid loss of central vision in the retina where macular degeneration has occurred. This condition develops when the small blood vessels beneath the macula of the retina swarm and ooze out fluids like blood. While the rest of the retina is involved in the peripheral vision, the macula is responsible for the central vision, necessary for reading or identifying faces. Symptoms are effectively controlled by early intervention, and medications like anti-VEGF injections can delay the progression of the condition.
Wet Macular Degeneration Market Growth Drivers
Increasing Aging Population to Boost the Market Growth
In a report, the World Health Organization (WHO) highlighted that with increasing life expectancy, a large number of individuals will reach 60 or older by 2050. Wet macular degeneration cases are bound to surge with the increasing incidence of the geriatric population base, leading to increased demand for treatment among the elderly with vision-related diseases.
FDA Approval Boosts the Market Growth
In September 2024, Pavblu, the fifth biosimilar referencing Eylea (aflibercept), was approved by the FDA for the treatment of retinal conditions such as wet age-related macular degeneration. Pavblu, developed by Amgen, was approved after a phase 3 study with 576 patients from various countries. It is one of several biosimilars that got approval in 2024, along with Yesafili, Opuviz, Ahzantive, and Enzeevu. There is a growing emphasis on early detection and preventive healthcare. Increasing approvals from essential regulatory authorities is expected to boost the market value in the forecast period.
Wet Macular Degeneration Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Development of Long-Acting Treatments
Companies are investigating extended-duration therapies for wet AMD to decrease the need for invasive surgeries and enhance patient adherence. Innovations such as port delivery systems and sustained-release formulations are designed to prolong injection intervals, possibly decreasing treatment demands and improving patient quality of life.
Emergence of Gene and Stem Cell Therapy to Boost Wet Macular Degeneration Market Demand
Gene and stem cell therapies demonstrate promise in targeting AMD. Researchers are striving to repair genetic mutations linked to wet macular degeneration and restore damaged retinal cells. Research studies show that there is a possibility of restoring vision and preventing disease progression in wet macular degeneration, indicating that these treatments may have a significant effect on the market for this condition.
Adoption of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnosis
Artificial Intelligence and machine learning are changing the landscape of retinal disease diagnosis by facilitating early detection and monitoring of macular degeneration, thus enhancing patient outcomes with prompt intervention. AI-driven diagnostic technology examines OCT images, recognizing levels of illness and tailoring treatment strategies.
Advancements in Treatment Options Drive Market Growth
New developments in the field of ophthalmology and biotechnology have made it possible to develop ways of treating wet macular degeneration. Novel technologies such as gene therapies and new ways of drug delivery as well as heightened interest in patient-specific approaches are stimulating the development of the market.
Wet Macular Degeneration Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Stage:
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
- Drugs
- Anti-vascular Endothelial Growth Factor
- Dietary Supplements
- Others
- Devices
- Glasses
- Contact Lenses
- Others
- Surgery
- Intravenous Route
- Intravitreal Route
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on the Route of Administration Set to Witness Substantial Growth
The market is segmented into intravenous route and intravitreal route based on the route of administration. Among these, the intravitreal method is expected to dominate the market because it directly administers drugs into the eye, resulting in improved treatment results and fewer overall side effects. Medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea) are often given through injections directly into the eye. This technique enables focused treatment of the retina, effectively preventing the growth of abnormal blood vessels. Due to its established efficacy and lower risks when compared to systemic delivery, intravitreal therapy continues to be considered the preferred treatment method for wet AMD.
Segmentation Based on End User Holds a Significant Market Share
The market is divided intohospitals, clinics, ambulatory surgical centers, homecare settings, and others. Among these, hospitals and clinics are expected to dominate the market because of their specialized ophthalmologists and advanced diagnostic equipment. They provide thorough treatment, which includes giving anti-VEGF medications such as Lucentis and Eylea via injections into the eye. Ambulatory surgical centers also hold a substantial share due to their affordability, while homecare settings are utilized for remote monitoring and occasional medical care.
Wet Macular Degeneration Market Analysis by Region
Based on region, the market report covers the United States, EU-4, and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. Due to advanced healthcare systems and substantial investment in research, the United States is expected to dominate the market. Factors like increasing elderly populations and lifestyle-related risks impact the market in this area. The government's backing promotes market expansion through leadership in clinical trials and innovative treatments such as targeted therapies and immunotherapies. The market is growing due to greater emphasis on early detection and personalized treatment choices.
Leading Players in the Wet Macular Degeneration Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG
Bayer AG, headquartered in Leverkusen, Germany, is a leading pharmaceutical company in the age-related wet macular degeneration (AMD) market. Their primary product, Eylea (aflibercept), is a very effective treatment for wet AMD that can preserve and even improve vision. Bayer remains committed to investing in the research and development of new AMD therapies.
F-Hoffmann La Roche Ltd.
Established in 1896 and headquartered in Basel, Switzerland. Roche specializes in ophthalmic disorder drugs. They developed Lucentis, a popular anti-VEGF therapy drug for wet AMD, through Genentech. They are working on new delivery methods and long-acting formulations to reduce reliance on frequent injections in AMD treatment, leveraging their biopharmaceutical expertise.
Pfizer Inc.
Pfizer Inc. is a significant player in the wet age-related macular degeneration (AMD) market, which is highly competitive and poised for growth due to the aging global population and the rising prevalence of eye disorders.
Novartis AG
Novartis AG is a leading player in the market, primarily through its flagship drug, Lucentis (ranibizumab), a pioneering anti-VEGF therapy developed in partnership with Genentech.
Other companies include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV, among others.
Key Questions Answered in the Wet Macular Degeneration Market
- What was the wet macular degeneration market value in 2024?
- What is the wet macular degeneration market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market breakup based on the disease stage?
- What is the market segmentation based on the treatment type?
- What is the market breakup based on the route of administration?
- What major factors aid the wet macular degeneration market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major wet macular degeneration market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players in the wet macular degeneration market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- How does the management of intermediate AMD differ from late-stage AMD?
- What role do anti-VEGF drugs play in wet AMD treatment?
- Why is the intravitreal route the preferred method for wet AMD treatment?
- Why does the United States lead the wet AMD market?
- What factors drive the wet AMD market in EU-4 and the UK?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Wet Macular Degeneration Market Overview – 8 Major Markets
- 3.1 Wet Macular Degeneration Market Historical Value 2018-2024
- 3.2 Wet Macular Degeneration Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Wet Macular Degeneration Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Wet Macular Degeneration Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Wet Macular Degeneration Market Landscape – 8 Major Markets
- 8.1 Wet Macular Degeneration Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Wet Macular Degeneration Market: Product Landscape
- 8.2.1 Analysis by Disease Stage
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Wet Macular Degeneration Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Wet Macular Degeneration Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Wet Macular Degeneration Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Wet Macular Degeneration Market 2018-2034 by Disease Stage
- 12.1.1 Market Overview
- 12.1.2 Early-Stage AMD
- 12.1.3 Intermediate AMD
- 12.1.4 Late-Stage AMD
- 12.2 Wet Macular Degeneration Market 2018-2034 by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Drugs
- 12.2.2.1 Anti-vascular Endothelial Growth Factor
- 12.2.2.2 Dietary Supplements
- 12.2.2.3 Others
- 12.2.3 Devices
- 12.2.3.1 Glasses
- 12.2.3.2 Contact Lenses
- 12.2.3.3 Others
- 12.2.4 Surgery
- 12.3 Wet Macular Degeneration Market 2018-2034 by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Intravenous Route
- 12.3.3 Intravitreal Route
- 12.4 Wet Macular Degeneration Market 2018-2034 by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Ambulatory Surgical Centers
- 12.4.4 Homecare Settings
- 12.4.5 Others
- 12.5 Wet Macular Degeneration Market 2018-2034 by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Wet Macular Degeneration Market 218-2034
- 13.1 United States Wet Macular Degeneration Market 2018-2034 by Disease Stage
- 13.1.1 Market Overview
- 13.1.2 Early-Stage AMD
- 13.1.3 Intermediate AMD
- 13.1.4 Late-Stage AMD
- 13.2 United States Wet Macular Degeneration Market 2018-2034 by Treatment Type
- 13.2.1 Market Overview
- 13.2.2 Drugs
- 13.2.2.1 Anti-vascular Endothelial Growth Factor
- 13.2.2.2 Dietary Supplements
- 13.2.2.3 Others
- 13.2.3 Devices
- 13.2.3.1 Glasses
- 13.2.3.2 Contact Lenses
- 13.2.3.3 Others
- 13.2.4 Surgery
- 13.3 United States Wet Macular Degeneration Market 2018-2034 by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Intravenous Route
- 13.3.3 Intravitreal Route
- 13.4 United States Wet Macular Degeneration Market 2018-2034 by End User
- 13.4.1 Market Overview
- 13.4.2 Hospitals & Clinics
- 13.4.3 Ambulatory Surgical Centers
- 13.4.4 Homecare Settings
- 13.4.5 Others
- 14 EU-4 and United Kingdom Wet Macular Degeneration Market 218-2034
- 14.1 EU-4 and United Kingdom Wet Macular Degeneration Market 2018-2034 by Disease Stage
- 14.1.1 Market Overview
- 14.1.2 Early-Stage AMD
- 14.1.3 Intermediate AMD
- 14.1.4 Late-Stage AMD
- 14.2 EU-4 and United Kingdom Wet Macular Degeneration Market 2018-2034 by Treatment Type
- 14.2.1 Market Overview
- 14.2.2 Drugs
- 14.2.2.1 Anti-vascular Endothelial Growth Factor
- 14.2.2.2 Dietary Supplements
- 14.2.2.3 Others
- 14.2.3 Devices
- 14.2.3.1 Glasses
- 14.2.3.2 Contact Lenses
- 14.2.3.3 Others
- 14.2.4 Surgery
- 14.3 EU-4 and United Kingdom Wet Macular Degeneration Market 2018-2034 by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Intravenous Route
- 14.3.3 Intravitreal Route
- 14.4 EU-4 and United Kingdom Wet Macular Degeneration Market 2018-2034 by End User
- 14.4.1 Market Overview
- 14.4.2 Hospitals & Clinics
- 14.4.3 Ambulatory Surgical Centers
- 14.4.4 Homecare Settings
- 14.4.5 Others
- 15 Japan Wet Macular Degeneration Market 218-2034
- 15.1 Japan Wet Macular Degeneration Market 2018-2034 by Disease Stage
- 15.1.1 Market Overview
- 15.1.2 Early-Stage AMD
- 15.1.3 Intermediate AMD
- 15.1.4 Late-Stage AMD
- 15.2 Japan Wet Macular Degeneration Market 2018-2034 by Treatment Type
- 15.2.1 Market Overview
- 15.2.2 Drugs
- 15.2.2.1 Anti-vascular Endothelial Growth Factor
- 15.2.2.2 Dietary Supplements
- 15.2.2.3 Others
- 15.2.3 Devices
- 15.2.3.1 Glasses
- 15.2.3.2 Contact Lenses
- 15.2.3.3 Others
- 15.2.4 Surgery
- 15.3 Japan Wet Macular Degeneration Market 2018-2034 by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Intravenous Route
- 15.3.3 Intravitreal Route
- 15.4 Japan Wet Macular Degeneration Market 2018-2034 by End User
- 15.4.1 Market Overview
- 15.4.2 Hospitals & Clinics
- 15.4.3 Ambulatory Surgical Centers
- 15.4.4 Homecare Settings
- 15.4.5 Others
- 16 India Wet Macular Degeneration Market 218-2034
- 16.1 India Wet Macular Degeneration Market 2018-2034 by Disease Stage
- 16.1.1 Market Overview
- 16.1.2 Early-Stage AMD
- 16.1.3 Intermediate AMD
- 16.1.4 Late-Stage AMD
- 16.2 India Wet Macular Degeneration Market 2018-2034 by Treatment Type
- 16.2.1 Market Overview
- 16.2.2 Drugs
- 16.2.2.1 Anti-vascular Endothelial Growth Factor
- 16.2.2.2 Dietary Supplements
- 16.2.2.3 Others
- 16.2.3 Devices
- 16.2.3.1 Glasses
- 16.2.3.2 Contact Lenses
- 16.2.3.3 Others
- 16.2.4 Surgery
- 16.3 India Wet Macular Degeneration Market 2018-2034 by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Intravenous Route
- 16.3.3 Intravitreal Route
- 16.4 India Wet Macular Degeneration Market 2018-2034 by End User
- 16.4.1 Market Overview
- 16.4.2 Hospitals & Clinics
- 16.4.3 Ambulatory Surgical Centers
- 16.4.4 Homecare Settings
- 16.4.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Pfizer Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Bayer AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 F-Hoffmann La Roche Ltd.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Novartis AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Panoptica Pharma
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Bausch + Lomb
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Regeneron Pharmaceuticals Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Ocugen Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 Oxurion NV
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 23.11 REGENXBIO Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Companies News and Developments
- 23.11.5 Certifications
- 24 Wet Macular Degeneration Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
